A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 1
140
about 3.2 years
18+
Male only
9 sites in CA, CT, FL +5
What this study is about
This trial is testing a new medication called ABBV-969 in people with advanced prostate cancer that has not responded to other treatments. The goal is to see if this medication is safe and how it works in the body. Participants will receive ABBV-969 through an IV infusion at different doses, and they will be monitored closely for any side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ABBV-969
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
intravenous
Primary: Percentage of Participants With Adverse Events (AEs)
Secondary: Area Under the Plasma/Serum Concentration Versus Time Curve (AUC) of ABBV-969, Maximum Observed Plasma Concentration (Cmax) of ABBV-969, Terminal Phase Elimination Half-Life (t1/2) of ABBV-969, Time to Maximum Observed Concentration (Tmax) of ABBV-969
Oncology